NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free LTRN Stock Alerts $8.80 -0.98 (-10.02%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$8.50▼$10.0650-Day Range$3.87▼$10.6552-Week Range$2.38▼$11.99Volume307,861 shsAverage Volume263,818 shsMarket Capitalization$94.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lantern Pharma alerts: Email Address Lantern Pharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 6 Articles This WeekInsider TradingSelling Shares$607,674 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.02) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.40 out of 5 starsMedical Sector898th out of 938 stocksPharmaceutical Preparations Industry404th out of 423 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lantern Pharma. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.83% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently increased by 112.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LTRN. Previous Next 2.9 News and Social Media Coverage News SentimentLantern Pharma has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lantern Pharma this week, compared to 1 article on an average week.Search Interest27 people have searched for LTRN on MarketBeat in the last 30 days. This is an increase of 1,250% compared to the previous 30 days.MarketBeat Follows15 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 275% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $607,674.00 in company stock.Percentage Held by InsidersOnly 6.92% of the stock of Lantern Pharma is held by insiders.Percentage Held by InstitutionsOnly 28.62% of the stock of Lantern Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lantern Pharma are expected to grow in the coming year, from ($2.02) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Lantern Pharma Stock (NASDAQ:LTRN)Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Read More LTRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LTRN Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comFY2024 EPS Estimates for Lantern Pharma Inc. (NASDAQ:LTRN) Decreased by HC WainwrightMarch 20, 2024 | seekingalpha.comLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 20, 2024 | americanbankingnews.comHC Wainwright Weighs in on Lantern Pharma Inc.'s Q1 2024 Earnings (NASDAQ:LTRN)March 19, 2024 | msn.comLTRN: 2023 ResultsMarch 19, 2024 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)March 19, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | investorplace.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023March 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 18, 2024 | benzinga.comRecap: Lantern Pharma Q4 EarningsMarch 18, 2024 | finance.yahoo.comLantern Pharma Inc Reports Progress and Financials for FY 2023March 18, 2024 | businesswire.comLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsMarch 16, 2024 | marketwatch.comLantern Pharma Up 20% After Dosing Initiated in Trial for Cancer Drug Developed with AIMarch 16, 2024 | finance.yahoo.comLTRN May 2024 5.000 callMarch 16, 2024 | finance.yahoo.comLTRN Apr 2024 12.500 callMarch 15, 2024 | benzinga.comLantern Pharma Earnings PreviewMarch 15, 2024 | finance.yahoo.comLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284March 14, 2024 | finance.yahoo.comLTRN Mar 2024 10.000 callMarch 11, 2024 | businesswire.comLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETMarch 8, 2024 | finance.yahoo.comLTRN Oct 2024 5.000 putMarch 8, 2024 | finance.yahoo.comLTRN Apr 2024 2.500 callMarch 7, 2024 | finance.yahoo.comLTRN Mar 2024 7.500 callMarch 5, 2024 | finance.yahoo.comLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceMarch 5, 2024 | businesswire.comLantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceMarch 4, 2024 | finance.yahoo.comLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesFebruary 28, 2024 | msn.comAfter Taiwan's striking lantern festival, school kids help clean up the messFebruary 23, 2024 | benzinga.comLantern Pharma Stock (NASDAQ:LTRN) Dividends: History, Yield and DatesSee More Headlines Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2023Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees22Year Founded2013Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.11% Return on Assets-32.19% Debt Debt-to-Equity RatioN/A Current Ratio16.18 Quick Ratio16.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.76 per share Price / Book2.34Miscellaneous Outstanding Shares10,740,000Free Float9,998,000Market Cap$94.51 million OptionableOptionable Beta1.28 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Panna Sharma PH.D. (Age 53)President, CEO & Director Comp: $633.25kMr. David R. Margrave (Age 63)CFO & Secretary Comp: $394.36kDr. Kishor Gopaldas Bhatia Ph.D. (Age 69)Chief Scientific Officer & Scientific Consultant Comp: $184.33kNicole LeberInvestor Relations Associate, Finance & Administrative CoordinatorDr. Peter L. Nara D.V.M.M.S., Ph.D., Co-Founder & AdvisorMr. Ernest Kitt B.S.M.S, Head of Clinical OperationsMore ExecutivesKey CompetitorsCyteir TherapeuticsNASDAQ:CYTTReviva PharmaceuticalsNASDAQ:RVPHVincerx PharmaNASDAQ:VINCOramed PharmaceuticalsNASDAQ:ORMPAdageneNASDAQ:ADAGView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 2,120 shares on 3/11/2024Ownership: 3.427%Aaron G.L. FletcherSold 74,297 sharesTotal: $360,340.45 ($4.85/share)Citadel Advisors LLCSold 6,400 shares on 2/15/2024Ownership: 0.000%Redmond Asset Management LLCSold 5,844 shares on 2/12/2024Ownership: 0.374%Meridian Wealth Management LLCBought 3,000 shares on 2/8/2024Ownership: 0.181%View All Insider TransactionsView All Institutional Transactions LTRN Stock Analysis - Frequently Asked Questions Should I buy or sell Lantern Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LTRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares. View LTRN analyst ratings or view top-rated stocks. How have LTRN shares performed in 2024? Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN stock has increased by 105.6% and is now trading at $8.80. View the best growth stocks for 2024 here. Are investors shorting Lantern Pharma? Lantern Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 144,600 shares, an increase of 112.6% from the February 29th total of 68,000 shares. Based on an average daily volume of 243,300 shares, the short-interest ratio is presently 0.6 days. Currently, 1.8% of the company's shares are sold short. View Lantern Pharma's Short Interest. When is Lantern Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LTRN earnings forecast. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings results on Monday, March, 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same quarter in the prior year, the company posted ($0.31) earnings per share. What ETFs hold Lantern Pharma's stock? ETFs with the largest weight of Lantern Pharma (NASDAQ:LTRN) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK). When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. Who are Lantern Pharma's major shareholders? Lantern Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.43%), Redmond Asset Management LLC (0.37%), Pathway Financial Advisors LLC (0.26%), Meridian Wealth Management LLC (0.18%), Sigma Planning Corp (0.11%) and Dimensional Fund Advisors LP (0.11%). Insiders that own company stock include Aaron GL Fletcher and Leslie W Kreis. View institutional ownership trends. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LTRN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.